CTRI/2023/07/055120已完成2 期
A randomized double-blinded placebo-controlled study to determine the efficacy of Turmeric-Boswellia formulation on subjects with low back soreness and discomfort. - Nil
Arjuna Natural Private Ltd0 个研究点目标入组 52 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Male or female 18 to 70 years of age
- •Posture related low back pain
- •NRS score greater than 5 pain at the time of screening.
- •BMI 18 to 29kg/m2
排除标准
- •History of herniated or ruptured disc, Sciatica, inflammatory arthropathy, severe rheumatoid arthritis, severe osteoarthritis, fibromyalgia, gout, kidney infection, failure or stones, scoliosis or spondylolisthesis, Past injuries like fractures, tears or trauma to the spine, and tumour or spinal cancer.
- •Acute 48-hour pain due to some exercise.
- •Knee surgery within the past 6 months, expectations of surgery in the next 4 months, Intra-articular corticosteroid injections within the preceding 3 months.
- •No neurological symptoms like numbness or weakness in the legs. Muscle pain does not involve compression or irritation of the spinal nerves.
- •BMI greater or eqaul to 30
- •High alcohol intake greater than 2 standard drinks per day
- •Smoking status not more than 1 pack per day
- •Concomitant medications antibiotics, NSAIDS, steroids, OTC pills and ointments for pain 1 week before screening. Patients taking any joint pain supplements
研究者
相似试验
进行中（未招募）
1 期
Study of efficacy and safety of canakinumab in patients with Hereditary Periodic FeversHereditary Periodic Fevers (TRAPS, HIDS, or crFMF)MedDRA version: 18.0Level: PTClassification code 10016207Term: Familial mediterranean feverSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 18.0Level: LLTClassification code 10067783Term: Tumor necrosis factor receptor-associated periodic syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 18.0Level: PTClassification code 10072010Term: Hyper IgD syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2013-004291-35-HUovartis Pharma Services AG180
已完成
2 期
A randomized, double-blind, placebo controlled study to assess the pharmacodynamics, safety/tolerability and efficacy of omiganan in patients with mild to moderate atopic dermatitiseczema10014982atopic dermatitisNL-OMON42598Cutanea Life Sciences36
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia SyndromeEUCTR2011-005535-68-NLovartis Pharma Services AG42
已完成
3 期
A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia SyndromeFamilial Chylomicronemia Syndrome10013317NL-OMON39328ovartis4
进行中（未招募）
不适用
A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia SyndromeFamilial Chylomicronemia Syndrome (FCS)MedDRA version: 14.1Level: PTClassification code 10051598Term: ChylomicronsSystem Organ Class: 10022891 - InvestigationsEUCTR2011-005535-68-DEovartis Pharma Services AG42